logo

Minerva Neurosciences Inc (NERV)



Trade NERV now with
  Date
  Headline
4/9/2018 8:32:37 AM Minerva Neurosciences Screens First Patient In Phase 2b Trial Of MIN-117 To Treat Major Depressive Disorder
3/12/2018 7:36:35 AM Minerva Neurosciences Q4 Net Income $0.2 Mln Or Breakeven Per Share Vs Loss Of $9.4 Mln Or $0.27/Shr Last Year
2/5/2018 8:36:10 AM Minerva Neurosciences Names Rémy Luthringer Executive Chairman And William Doyle As Lead Independent Director
12/21/2017 8:05:56 AM Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2b Trial Comparing Seltorexant
12/19/2017 8:07:30 AM Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
12/11/2017 4:37:05 PM Minerva Neurosciences Names Richard Russell As President
12/11/2017 8:17:38 AM Minerva Neurosciences Elects William Doyle And Hans Peter Hasler To Board
8/25/2017 8:31:17 AM Minerva Neurosciences Reports European Commission Approval Of Amendment Of MIN-202 Agreement With Janssen
8/3/2017 7:49:31 AM Minerva Neurosciences Q2 Net Loss $9.8 Mln Or $0.27/shr Vs. Net Loss $5.2 Mln Or $0.18/shr Last Year
7/24/2017 8:32:40 AM Minerva Neurosciences: Michele Ollier And Nico Vandervelpen Resign From Board
7/5/2017 10:04:05 AM Diasome Pharma Receives Funding Led By Medicxi
6/22/2017 8:34:51 AM Minerva Reports Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase 3 Trial